The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in PD Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05437003
Recruitment Status : Completed
First Posted : June 29, 2022
Last Update Posted : February 16, 2024
Sponsor:
Information provided by (Responsible Party):
NeuraLight

Brief Summary:

This is a prospective study in a cohort of about 500 patients with Idiopathic Parkinson's disease, examined routinely in the neurological outpatient clinic.

This study aims to evaluate the correlation between oculometric measures and clinical endpoints. Subjects will be evaluated following a physician examination.The evaluations will include MDS-UPDRS examination, as well as an oculometric evaluation for eye movements. In addition, 500 healthy subjects will be evaluated.


Condition or disease Intervention/treatment Phase
Idiopathic Parkinson Disease Other: NeuraLight software-based platform Not Applicable

Detailed Description:

This is a prospective study in a cohort of patients with idiopathic PD who are visiting the Parkinson's outpatient clinic. The aim of the study is to evaluate the correlation between oculometric measures and MDS-UPDRS score in subjects who meet the inclusion criteria and who provide a signed Informed Consent.

This study is designed to evaluate the correlation between oculometric measures and the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Subjects will be evaluated at their visit to the clinic. The evaluations will include an MDS-UPDRS examination by a certified neurologist and other tests. In addition, all patients will undergo a NeuraLight session for oculometric evaluation along with eye-tracking recordings. All assessments will be performed during a clinic visit unless authorized to be conducted remotely. In addition, 500 healthy subjects will be evaluated, undergoing a NeuraLight session for oculometric evaluation along with eye-tracking recordings.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 465 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Cross-Sectional Study to Evaluate the Correlation Between Oculometric Measures and MDS-UPDRS in Patients With Idiopathic Parkinson's Disease (PD) and Evaluation of Oculometric Measures in Healthy Participants
Actual Study Start Date : August 20, 2022
Actual Primary Completion Date : February 15, 2024
Actual Study Completion Date : February 15, 2024


Arm Intervention/treatment
Experimental: PD patients visiting clinic
All patients will undergo a NeuraLight session for oculometric evaluation along with eye-tracking recordings. All assessments will be performed during a clinic visit unless authorized to be conducted remotely.
Other: NeuraLight software-based platform
NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including PD patients

Experimental: Healthy subjects
All patients will undergo a NeuraLight session for oculometric evaluation along with eye-tracking recordings. All assessments will be performed during a visit unless authorized to be conducted remotely.
Other: NeuraLight software-based platform
NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including PD patients




Primary Outcome Measures :
  1. Correlation between MDS-UPDRS score and its parts with NeuraLight oculometric measurements [ Time Frame: 12 months ]
    The correlation between MDS-UPDRS score and its parts with NeuraLight oculometric measurements (R-Square>0.5, p<0.05) according to the Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at every visit

  2. Feasibility of using NeuraLight system to capture oculometric measures in a cohort of PD patients and healthy subjects [ Time Frame: 12 months ]
    Capturing >50 different oculometric measures in >95% of a cohort of about 1000 patients

  3. Comparison of NeuraLight extracted oculometric measures with a validated eye-tracking system [ Time Frame: 12 months ]
    Relative root mean square error (RMSE) of NeuraLight's extracted oculometric measures compared with retrieved measurements from a validated eye tracking system <0.1


Secondary Outcome Measures :
  1. Using the retrieved data of collected NeuraLight oculometric measures for calibration of prediction models of MDS-UPDRS clinical endpoint [ Time Frame: 12 months ]
    Optimization of a feature selection model (Fisher's Linear Discriminant Analysis (LDA)) on NeuraLight oculometric measures used for a logistic regression model of MDS-UPDRS with a relative root mean square error (RMSE) of <0.1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

PD patients:

Inclusion Criteria:

  • Men and women with idiopathic PD (Hoehn & Yahr scale 1-5)
  • Age between 18 and 85 years old
  • Normal or corrected vision
  • Ability to follow instructions
  • Willing and able to sign an informed consent form

Exclusion Criteria:

  • Inability to sit for 20 minutes on a chair in a calm manner
  • Personal or 1st degree relative history of epilepsy
  • Additional neurological diseases
  • Drug or alcohol abuse

Healthy subjects:

Inclusion Criteria:

  • Age between 18 and 85 years old
  • Normal or corrected vision
  • Ability to follow instructions
  • Willing and able to sign an informed consent form

Exclusion Criteria

  • Inability to sit for 20 minutes on a chair in a calm manner
  • Personal or 1st degree relative history of epilepsy
  • Neurological diseases
  • Drug or alcohol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05437003


Locations
Layout table for location information
Israel
Rabin Medical Center
Petach Tikva, Israel, 4941492
Sponsors and Collaborators
NeuraLight
Investigators
Layout table for investigator information
Principal Investigator: Johnathan Reiner, MD Sackler Faculty of Medicine, Tel Aviv University
Publications:
Layout table for additonal information
Responsible Party: NeuraLight
ClinicalTrials.gov Identifier: NCT05437003    
Other Study ID Numbers: NL/PD/2022-1
First Posted: June 29, 2022    Key Record Dates
Last Update Posted: February 16, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is not plan to share IPD with other researchers

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases